SRS Capital Advisors Inc. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 428 shares of the life sciences company’s stock, valued at approximately $157,000.

A number of other hedge funds have also bought and sold shares of ILMN. Millennium Management LLC raised its stake in shares of Illumina by 219.8% in the 2nd quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock valued at $153,318,000 after purchasing an additional 377,283 shares during the period. WCM Investment Management CA acquired a new stake in shares of Illumina in the 3rd quarter valued at about $77,035,000. Jennison Associates LLC raised its stake in shares of Illumina by 4.5% in the 2nd quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock valued at $1,200,271,000 after purchasing an additional 185,745 shares during the period. First Trust Advisors LP raised its stake in shares of Illumina by 42.0% in the 3rd quarter. First Trust Advisors LP now owns 474,686 shares of the life sciences company’s stock valued at $174,238,000 after purchasing an additional 140,364 shares during the period. Finally, Fred Alger Management Inc. raised its stake in shares of Illumina by 21.4% in the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock valued at $217,413,000 after purchasing an additional 137,302 shares during the period. Hedge funds and other institutional investors own 89.90% of the company’s stock.

In other news, EVP Marc Stapley sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $336.68, for a total transaction of $336,680.00. Following the completion of the sale, the executive vice president now owns 7,757 shares in the company, valued at $2,611,626.76. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert S. Epstein sold 1,346 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $345.14, for a total value of $464,558.44. Following the sale, the director now owns 7,139 shares of the company’s stock, valued at approximately $2,463,954.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,464 shares of company stock worth $17,883,331. 0.54% of the stock is owned by company insiders.

ILMN has been the topic of several recent research reports. Morgan Stanley lifted their price target on Illumina from $195.00 to $210.00 and gave the company an “underweight” rating in a research note on Friday, July 13th. UBS Group initiated coverage on Illumina in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 price target on the stock. BidaskClub downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Cowen lifted their price target on Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a research note on Thursday, September 6th. Finally, ValuEngine downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $330.94.

NASDAQ:ILMN opened at $329.25 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The stock has a market capitalization of $50.37 billion, a P/E ratio of 82.31, a P/E/G ratio of 2.54 and a beta of 1.07. Illumina, Inc. has a 52-week low of $203.83 and a 52-week high of $372.61.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.26. The business had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. Illumina’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.11 earnings per share. On average, analysts anticipate that Illumina, Inc. will post 5.75 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/11/10/428-shares-in-illumina-inc-ilmn-acquired-by-srs-capital-advisors-inc.html.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: What are the reasons investors use put options?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.